SCHEMBL506497

SCHEMBL506497

COc1cccnc1CO

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
PLAU P00749 1/20 0.49
PDGFRB P09619 1/20 0.44
PDGFRA P16234 1/20 0.44
CBFB Q13951 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
LMNA P02545 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA12 O43570 1/20 0.42
CA4 P22748 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
ADORA2A P29274 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11095592 0.98 ALDH1A1 (0.53) ALDH1A1L3MBTL1PLAUPDGFRBPDGFRA
SCHEMBL932223 0.86 L3MBTL1 (0.46) ALDH1A1L3MBTL1PLAUPDGFRBPDGFRA
SCHEMBL2645036 0.84 ALDH1A1 (0.52) ALDH1A1L3MBTL1PLAUSMN1; SMN2NPC1
SCHEMBL8371346 0.83 PLAU (0.44) ALDH1A1L3MBTL1PLAUPDGFRBPDGFRA
SCHEMBL6628054 0.82 ALDH1A1 (0.50) ALDH1A1L3MBTL1PLAUCBFBSMN1; SMN2
SCHEMBL20099911 0.82 ALDH1A1 (0.42) ALDH1A1L3MBTL1PLAUPDGFRBPDGFRA
SCHEMBL507177 0.82 PLAU (0.43) ALDH1A1L3MBTL1PLAUPDGFRBPDGFRA
SCHEMBL4475474 0.82 PLAU (0.47) ALDH1A1L3MBTL1PLAUPDGFRBPDGFRA
SCHEMBL29636120 0.82 PLAU (0.43) ALDH1A1L3MBTL1PLAUPDGFRBPDGFRA
SCHEMBL8497269 0.82 PLAU (0.43) ALDH1A1L3MBTL1PLAUPDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 US disclosed
EP-4587014-A2 C5AR1 ANTAGONISTS AND USES THEREOF Vanqua Bio, Inc. (US) 2025-07-23 EP disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 US disclosed
US-20240368133-A1 Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling CONFO THERAPEUTICS N.V. (BE) 2024-11-07 US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 WO disclosed
CN-118159530-A Compounds for the treatment of pain, in particular neuropathic pain and/or other diseases or disorders associated with AT2R and/or AT2R mediated signalling 康福治疗有限公司 2024-06-07 CN disclosed
CN-1069882-A The Compounds and methods for that suppresses HIV and correlated virus MEDIVIR AB (CH) 1993-03-17 CN disclosed
WO-1993003022-A1 COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES MEDIVIR AB (SE) 1993-02-18 WO disclosed
US-4426526-A HISTAMINE ANTAGONISTS, ANTIINFLAMMATORY, ANTISECRETORY SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1984-01-17 US disclosed
US-4264608-A HISTAMINE ANTAGONISTS SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1981-04-28 US disclosed
US-4215126-A HISTAMINE H2 BLOCKING SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1980-07-29 US disclosed
US-4173644-A HISTAMINE ANTAGONISTS, ANTIINFLAMMATORY AGENTS, ANTISECRETORY AGENTS SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1979-11-06 US disclosed
US-4156727-A ANTIHISTAMINES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1979-05-29 US disclosed
US-4154838-A ANTIHISTAMINE SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1979-05-15 US disclosed
US-4120972-A HISTAMINE HYDROGEN-ANTAGONISTS SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1978-10-17 US disclosed
US-4120966-A ANTIHISTAMINES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1978-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368133-A1 Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling AGTR2, AGTR1, OPRL1 ALDH1A1 2919/4885L3MBTL1 3960/4885PLAU 3125/4885
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB ALDH1A1 3824/4885L3MBTL1 2775/4885PLAU 3171/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB ALDH1A1 3824/4885L3MBTL1 2775/4885PLAU 3171/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB ALDH1A1 3824/4885L3MBTL1 2775/4885PLAU 3171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.